NMDA Receptor Antagonists Increase the Release of GLP-1 From Gut Endocrine Cells

Type 2 diabetes mellitus (T2DM) remains one of the most pressing health issues facing modern society. Several antidiabetic drugs are currently in clinical use to treat hyperglycaemia, but there is a need for new treatments that effectively restore pancreatic islet function in patients. Recent studie...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Malgorzata Cyranka, Thomas Monfeuga, Natascia Vedovato, Chelsea M Larabee, Anandhakumar Chandran, Enrique M Toledo, Heidi de Wet
Format:	Artigo
Sprog:	Inglês
Udgivet:	Frontiers Media S.A. 2022-04-01
Serier:	Frontiers in Pharmacology
Fag:	NMDA receptor (NMDAR) Glucagon-like peptide 1 (GLP-1) GLUTag cells MK-801 (dizocilpine) dextromethorphan (DMO), NMDA receptor antagonist
Online adgang:	https://www.frontiersin.org/articles/10.3389/fphar.2022.861311/full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!